These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38724245)

  • 1. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
    Watanabe R; Ebina K; Gon T; Okano T; Murata K; Murakami K; Maeda Y; Jinno S; Shirasugi I; Son Y; Amuro H; Katayama M; Hara R; Hata K; Yoshikawa A; Yamamoto W; Tachibana S; Hayashi S; Etani Y; Katsushima M; Fukumoto K; Yamada S; Hashimoto M
    Rheumatology (Oxford); 2024 Sep; 63(9):2418-2426. PubMed ID: 38724245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
    Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
    Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis.
    Anno S; Okano T; Mamoto K; Yamada Y; Mandai K; Orita K; Iida T; Tada M; Inui K; Koike T; Nakamura H
    Mod Rheumatol; 2024 Aug; ():. PubMed ID: 39215592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
    Novella-Navarro M; Ruiz-Esquide V; López-Juanes N; Chacur CA; Monjo-Henry I; Nuño L; Peiteado D; Villalba A; Fernández-Fernandez E; Sanz-Jardón M; Kafati M; Sanmartí R; Plasencia-Rodríguez C; Balsa A
    Clin Rheumatol; 2024 Sep; 43(9):2817-2823. PubMed ID: 39009920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
    Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
    Qi W; Robert A; Singbo N; Ratelle L; Fortin PR; Bessette L; Brown JP; Michou L
    Adv Rheumatol; 2024 Aug; 64(1):55. PubMed ID: 39107865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
    Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A
    Rheumatology (Oxford); 2024 Nov; 63(11):3065-3073. PubMed ID: 37988163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
    Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
    Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat.
    D'Onofrio B; De Stefano L; Bozzalla Cassione E; Morandi V; Cuzzocrea F; Sakellariou G; Manzo A; Montecucco C; Bugatti S
    Arthritis Res Ther; 2024 Nov; 26(1):192. PubMed ID: 39516929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
    Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
    Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Aug; 60(8):3778-3788. PubMed ID: 33331946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
    Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
    Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
    Kwon OC; Choi W; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
    Adv Rheumatol; 2024 Apr; 64(1):26. PubMed ID: 38622706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.